Evidence map›Paper›PMID 39499285›Full record

ArticlePediatric cardiology2025

Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease.

Sindhu Pandurangi, Michael E Kim, Nicolas Noriega, Bradley Conant, JangDong Seo, Reena Mourya, Pranavkumar Shivakumar, Anna L Peters, Andrew Misfeldt, Meghan Chlebowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sindhu Pandurangi *Children's Medical Center of Dallas and Division of Pediatric Gastroenterology, Hepatology, and Nutrition of the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Michael E Kim *Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Nicolas NoriegaDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Bradley ConantDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
JangDong SeoDivision of Pediatric Cardiology, Heart Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.
Reena MouryaChildren's Medical Center of Dallas and Division of Pediatric Gastroenterology, Hepatology, and Nutrition of the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Pranavkumar ShivakumarChildren's Medical Center of Dallas and Division of Pediatric Gastroenterology, Hepatology, and Nutrition of the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Anna L PetersDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Andrew MisfeldtDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Meghan ChlebowskiDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. meghan.chlebowski@cchmc.org.

Funding

PEDIATRIC GASTROENTEROLOGY AND NUTRITION TRAINING GRANTT32DK007727 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Phillip P Minar · 1995 to 2026
$11.3M
NIDDK NIH HHS T32 DK007727NIH HHS T32 DK007727
6 · The paper itself

Abstract

backgroundMatrix metalloproteinase 7 (MMP-7) is a novel biomarker for diagnosis of biliary atresia (BA), the most common cholestatic liver disease in infancy. There is a pressing need to determine the utility of MMP-7 levels in infants with congenital heart disease (CHD) to avoid unnecessary invasive diagnostic procedures in this high-risk population. We investigated the utility of MMP-7 in discriminating BA from non-BA cholestasis in infants with CHD and whether MMP-7 elevation was present in infants requiring treatment for clinically significant PH.

methodsThis is a single-center cross-sectional study including infants < 180 days of age with cholestasis and serum MMP-7 levels collected from 2019 to 2023. Demographic data and descriptive statistics were summarized with medians with interquartile ranges and frequencies with percentages. Median MMP-7 levels were assessed via Wilcoxon rank-sum test.

resultsA total of 149 patients were included. Patients with CHD had significantly elevated MMP-7 levels relative to the non-CHD cohort (50 vs. 34 ng/mL, p = 0.009). Sub-analysis comparing infants with and without PH revealed significantly elevated median MMP-7 levels in those with clinically significant PH (125 vs. 39 ng/mL, p = 0.010). CHD patients with PH had greater median MMP-7 compared to CHD patients without PH (154 vs 43 ng/mL, p = 0.028).

conclusionSerum MMP-7 levels in infants with congenital heart disease with cholestasis (CHD-C) were significantly elevated compared to those with cholestasis alone. MMP-7 may help identify non-BA cholestatic infants who have concurrent clinically significant pulmonary hypertension. Larger, prospective studies are needed to validate this finding and establish CHD-specific MMP-7 cut-offs.

Indexed as

Biliary AtresiaCholestasisHeart Defects, CongenitalMatrix Metalloproteinase 7BiomarkersCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMaleBiomarkersMatrix Metalloproteinase 7MMP7 protein, humanBiliary atresiaBiomarkerCholestasisCongenital heart diseaseMMP-7Pulmonary hypertension

Identifiers

PMID39499285
PMCPMC12264905

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.